Dr. Sara Gottfried strongly recommends a Coronary Artery Calcium (CAC) score, a CT scan of the chest, for all women by age 45. This simple, self-orderable test provides a critical assessment of cardiometabolic health, enabling early, personalized intervention for heart disease risk.

The number of Americans recommended for statins ballooned from 13 million to 56 million due to progressively lowered cholesterol thresholds. The expert committees setting these guidelines often had members with financial ties to drug makers, creating a conflict of interest.

A pragmatic approach to heart screening is to use the cheap, non-invasive Calcium CT (CAC) scan as a first-line filter. If the result is zero, further testing may be unnecessary. A non-zero score, indicating a propensity to build plaque, then justifies the more invasive and expensive ($2,000+) angiogram to assess soft plaques and blockage levels. This tiered strategy makes advanced screening accessible and cost-effective.

Decades ago, a legislative battle pitted preventative technology (calcium CT scanners) against treatment solutions (stents). The stent lobby won, shaping medical standards to favor profitable, reactive procedures over inexpensive, proactive screening. This regulatory capture explains why cholesterol remains the primary marker despite its flaws, hindering widespread adoption of more effective preventative tools.

Standard cholesterol tests are poor predictors of heart attacks, as 50% of victims fall within the 'normal' range. This reliance on an incomplete metric means millions of people, including those with healthy lifestyles, may have a false sense of security about their heart health, overlooking the more definitive presence of arterial plaque.

Focusing solely on LDL is a mistake. Even individuals with a genetic mutation leading to lifelong low LDL levels can still have cardiovascular events if they have other unmanaged risk factors like metabolic syndrome, obesity, or diabetes, highlighting the need for a comprehensive approach.

Relying on blood lipid panels (LDL, etc.) to assess cardiovascular risk is misleading, as they don't confirm arterial plaque. A CT angiography (CCTA), like a Cleerly scan, provides direct imaging of both hard and soft plaque, offering a far more accurate assessment of actual heart disease risk.

Medical lab test ranges define 'normal' by the average of the current population. In a society where 75% are overweight, this standard is not optimal. This creates a false sense of security, as being 'normal' might still mean being on a trajectory toward chronic disease.

The body endogenously produces all the cholesterol necessary for vital functions. Optimal LDL levels are around 40 mg/dL, similar to a newborn's. Higher levels, typically from diet, are not needed and function like a toxin, initiating atherosclerosis.